Recent Advances in the Research and Development of RAF Kinase Inhibitors

作者：Roger A. Smith, Jacques Dumas, Lila Adnane, Scott M. Wilhelm · 发表于：Current Topics in Medicinal Chemistry · 年份：2006 · DOI：10.2174/156802606777812077 · 被引用次数：48 · 研究领域：Melanoma and MAPK Pathways、Computational Drug Discovery Methods、Cancer Mechanisms and Therapy

The RAS-RAF-MEK-ERK signaling pathway (ERK pathway) plays a key role in tumorigenesis and cancer progression. Mutations of RAS or B-RAF lead to a constitutive activation of the ERK pathway, which ultimately results in increased cell division, and cell survival. This review article focuses on the recent literature related to ERK pathway inhibitors, with a particular emphasis on RAF kinase inhibitors. Preclinical and clinical data for the RAF kinase inhibitor sorafenib (BAY 43-9006 tosylate), that was recently approved in the US for the treatment of advanced renal cell carcinoma, are also outlined.